早期心脏转甲状腺素蛋白淀粉样变性的特征与自然史
本研究回顾性分析了879例未接受疾病修饰治疗的NAC ATTR Stage I期ATTR-CM患者,发现NT-proBNP、TTR基因型和肌钙蛋白T独立关联死亡。将Stage I进一步分为Ia和Ib后,Ib期中位生存75个月,Ia期超过100个月,且Ia期生存与一般人群相当。
要点
- NAC ATTR Stage I期患者可依据NT-proBNP和利尿剂需求进一步分层。
- Stage Ib期中位生存75个月,死亡风险为Ia期的5.06倍。
- Stage Ia期短期和中期生存良好,但仍有显著心血管疾病负担。
核心结论
- NAC ATTR Stage I期ATTR-CM患者可依据诊断时NT-proBNP浓度和利尿剂需求进一步分层为Ia和Ib期。
- Stage Ia期患者短期和中期生存良好,与一般人群相当,但仍有显著心血管疾病负担。
研究设计与样本
- 回顾性多中心观察性研究,纳入879例野生型TTR或携带p.V142I变异的ATTR-CM患者,诊断时为NAC ATTR Stage I期且未接受疾病修饰治疗。
主要发现
- Cox回归显示,诊断时与死亡独立相关的因素为NT-proBNP、TTR基因型和肌钙蛋白T。
- 88%患者为NAC ATTR Stage Ib期,中位估计生存75个月(95%CI 57-93),12%为Stage Ia期,生存超过100个月。
- Stage Ib期较Ia期死亡风险比为5.06(95%CI 1.23-20.87),P=0.025。
- 英国NAC ATTR Stage Ia期患者估计生存与英国一般人群对照相当(P=0.297)。
- 诊断时即存在显著心血管疾病负担,随访期间增加,包括Stage Ia期诊断的患者。
关键数值与推荐
- NAC ATTR Stage Ia定义为呋塞米等效利尿剂需求<0.75 mg/kg,且NT-proBNP≤500 ng/L(合并房颤时≤1000 ng/L)。
- NAC ATTR Stage Ib包括其余所有Stage I期患者。
临床怎么用
- 对NAC ATTR Stage I期ATTR-CM患者,应结合NT-proBNP和利尿剂需求进一步风险分层。
- Stage Ia期患者虽生存良好,仍需关注其心血管疾病负担。
局限性
- 回顾性观察性设计。
- 仅纳入野生型TTR或p.V142I变异患者。
- 患者均未接受疾病修饰治疗,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of early-stage ATTR-CM remains poorly characterized. METHODS AND RESULTS: A retrospective multi-centre observational study of 879 patients with ATTR-CM, either wild-type TTR genotype or carrying the p.V142I TTR variant, and NAC ATTR Stage I biomarkers at the time of diagnosis who did not receive disease-modifying therapy for amyloidosis. Disease characteristics at diagnosis that were independently associated with mortality by Cox regression analysis were N-terminal pro-B-type natriuretic peptide (NT-proBNP), TTR genotype, and troponin T. Patients were categorized into NAC ATTR Stage Ia, defined as a furosemide equivalent diuretic requirement of <0.75 mg/kg and an NT-proBNP ≤500 ng/L or ≤1000 ng/L in the presence of atrial fibrillation, and NAC ATTR Stage Ib comprising all remaining Stage I patients. Median estimated survival among the 88% NAC ATTR Stage Ib patients was 75 (95% CI 57-93) months compared with >100 months in the 12% with Stage Ia disease [hazard ratio for death 5.06 (95% confidence interval 1.23-20.87); P = 0.025] despite significant cardiovascular morbidity at the time of diagnosis which increased during follow-up, including among patients diagnosed in NAC ATTR Stage Ia. Estimated survival among UK NAC ATTR Stage Ia patients was comparable to UK general population controls (P = 0.297). CONCLUSION: Patients with NAC ATTR Stage I ATTR-CM can be further stratified according to NT-proBNP concentration and diuretic requirement at diagnosis. Patients with Stage Ia ATTR-CM have significant cardiovascular morbidity despite good short- and mid-term survival.
引用
- Law S, Bezard M, Petrie A, et al. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Eur Heart J. 2022. PMID: 35608040. doi:10.1093/eurheartj/ehac259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。